Prevalence and Severity of Depression in Coronary Artery Disease Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAl-Nahrain University
About this trial
This observational study aims to estimate the prevalence and severity of depression among patients with coronary artery disease (CAD) in Baghdad, Iraq, using the self-administered PHQ-9 questionnaire. The study seeks to answer the following questions:
What is the prevalence of depression among CAD patients? How is the severity of depression distributed within this group? Are specific demographic, clinical, or environmental factors associated with higher levels of depression?
Participants will:
Complete the PHQ-9 to assess the severity of depressive symptoms at a specific point in time.
Provide demographic and clinical information, including age, gender, socioeconomic status, comorbidities, and CAD-related factors such as type of intervention and duration of illness, to explore potential correlations with depression.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosed with coronary artery disease (confirmed through clinical, imaging, or procedural evidence).
Receiving care at designated hospitals in Baghdad.
Able to understand and complete the PHQ-9 questionnaire independently or with minimal assistance.
Consents to participate in the study.
Disqualifiers
Patients with a history of severe psychiatric disorders unrelated to depression (e.g., schizophrenia, bipolar disorder).
Patients with cognitive impairments or neurological conditions affecting their ability to complete the questionnaire.
Those currently hospitalized for acute cardiac events (e.g., myocardial infarction) requiring intensive care.
Individuals unwilling to provide informed consent.
Trial population
The study will include adult patients diagnosed with coronary artery disease (CAD) who are receiving outpatient or inpatient care in selected hospitals in Baghdad, Iraq. Participants will represent a diverse population in terms of age, gender, socioeconomic status, and comorbid conditions. The study aims to capture the prevalence and severity of depression within this group, considering the physical and psychological burden associated with CAD. Efforts will be made to recruit a representative sample to ensure that findings are generalizable to the broader population of CAD patients in Baghdad.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Prevalence of Depression
Proportion of coronary artery disease patients in Baghdad who exhibit depressive symptoms.
Time frame
Data collection will occur over a 3-month period, with each participant completing the assessment at a single point during this time frame.2
Severity of Depression
The severity of depression in this study will be determined based on the scores obtained from the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 categorizes depression severity as follows: Minimal depression: Scores 0-4, indicating little to no symptoms. Mild depression: Scores 5-9, suggesting occasional symptoms that may not significantly affect daily functioning. Moderate depression: Scores 10-14, indicating more frequent symptoms that can interfere with daily life. Moderately severe depression: Scores 15-19, showing pronounced symptoms that significantly impact daily activities. Severe depression: Scores 20-27, with symptoms that are debilitating.
Time frame
Data collection will occur over a 3-months period, with each participant completing the PHQ-9 assessment at a single point during this time frame.3
Patient Health Questionnaire-9 (PHQ-9)
The total score can range from 0 to 27. Higher scores indicate greater severity of depression.
Time frame
Data collection will occur over a 3-months period, with each participant completing the PHQ-9 assessment at a single point during this time frame.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov